Adult-onset cerebello-brainstem dominant form of X-linked adrenoleukodystrophy presenting as multiple system atrophy: case report and literature review: Cerebello-brainstem dominant form of X-ALD by Ogaki, Kotaro et al.
Adult-onset cerebello-brainstem dominant form of X-linked 
adrenoleukodystrophy presenting as multiple system atrophy: 
Case report and literature review
Kotaro Ogaki, MD, Ph.D.1, Shunsuke Koga, M.D., Ph.D.1, Naoya Aoki, M.D.1, Wenlang Lin, 
Ph.D.1, Kinuko Suzuki, M.D.2, Owen A. Ross, Ph.D.1, and Dennis W. Dickson, M.D.1
1Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA
2Department of Neuropathology, Tokyo Metropolitan Geriatric Hospital and Institute of 
Gerontology, Tokyo, Japan, and Department of Pathology and Laboratory Medicine, University of 
North Carolina at Chapel Hill, NC USA
Abstract
X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder and is caused 
by ABCD1 mutations. A cerebello-brainstem dominant form that mainly involves the cerebellum 
and brainstem is summarized in a review of the literature, with autopsy confirmed cases 
exceedingly rare. We report a 69-year-old white man who was diagnosed with this rare disorder 
and describe neuropathologic, ultrastructural and genetic analyses. He did not have adrenal 
insufficiency or a family history of X-ALD or Addison’s disease. His initial symptom was 
temporary loss of eyesight at age 34 years. His major symptoms were chronic and progressive gait 
disorder, weakness in his lower extremities, and spasticity, as well as autonomic failure and 
cerebellar ataxia suggesting possible multiple system atrophy (MSA). He also had seizures, 
hearing loss, and sensory disturbances. His brain MRI showed no obvious atrophy or significant 
white matter pathology in cerebrum, brainstem or cerebellum. He died at age 69 years with a 
diagnosis of multiple system atrophy. Microscopic analysis showed mild, patchy myelin 
rarefaction with perivascular clusters of PAS-positive, CD68-positive macrophages in the white 
matter most prominent in the cerebellum and occipital lobe, but also affecting optic tract and 
internal capsule. Electron microscopy of cerebellar white matter showed cleft-like trilamellar 
cytoplasmic inclusions in macrophages typical of X-ALD, which prompted genetic analysis that 
revealed a novel ABCD1 mutation, p.R163G. Given the relatively mild pathological findings and 
long disease duration, it is likely that the observed pathology was the result of a slow and indolent 
disease process. We described a patient who had sporadic cerebello-brainstem dominant form of 
X-ALD with long clinical course, mild pathological findings, and an ABCD1 p.R163G 
substitution. We also review a total of 34 cases of adult-onset cerebello-brainstem dominant form 
of X-ALD. Although rare, X-ALD should be considered in the differential diagnosis of MSA.
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INTRODUCTION
X-linked adrenoleukodystrophy (X-ALD; OMIM #300100) is the most common 
peroxisomal disorder and is caused by ATP-binding cassette, sub-family D (ALD), member 1 
gene (ABCD1; OMIM #300371). Peroxisomal dysfunction elevates plasma and tissue levels 
of very long-chain fatty acids (VLCFA), which affects various tissues, including the adrenal 
cortex, testes, and the nervous system.1 The disease phenotype ranges from the severe 
childhood cerebral form to a mild adrenomyeloneuropathy (AMN) form.
The most common phenotype is AMN (40–46%), where disease onset typically occurs 
during the second and third decades of life.2 The clinical presentation includes a progressive, 
spastic gait, erectile dysfunction, abnormal sphincter control, and sensory disturbances due 
to the involvement of peripheral nerves.1, 3–5 The main lesions occur in the spinal cord and 
peripheral nerve.6 The second most frequent phenotype is a cerebral form (31–35%), which 
presents in childhood with visual disturbances, hearing loss, mental retardation, spastic gait, 
and seizures.2, 7 Onset of symptoms in boys is usually around 10 years of age, and the vast 
majority have a poor prognosis.1 Typically, the most severe lesions are found in the white 
matter of the cerebrum, especially the occipital white matter, but the cerebellum and 
brainstem are largely spared.2, 8 A rare phenotype of X-ALD, the “cerebello-brainstem 
dominant form,”9 in which the cerebellum and brainstem are mainly involved, has been 
estimated to account for 1–2% of ALD.2 Neuropathological reports of this rare form are 
exceedingly rare. This phenotype was firstly reported as “adrenoleukomyeloneuropathy 
presenting as spinocerebellar degeneration” by Marsden et al. in 1982,10 and it has been 
referred to by other names, such as “olivo-ponto-cerebellar form,”2 “cerebellar 
involvement, ”8 “ataxic variant,”11 or “spinocerebellar variant,”12 In this study we refer to 
this form as “cerebello-brainstem dominant form” because this term is all-inclusive.
We report a patient with adult-onset cerebello-brainstem dominant form of X-ALD with 
long disease duration, mild pathological findings, and a novel ABCD1 mutation. We review 
the literature of 34 patients with adult-onset cerebello-brainstem dominant form of X-ALD.
CLINICAL SUMMARY
The patient was a 69-year-old white man who had chronic neurological complaints. His 
family history was negative for neurologic disease. He had no children or living first degree 
relatives. At age 34 years, he had temporary loss of vision that lasted about three weeks, 
which was thought to be caused by optic neuritis due to multiple sclerosis (MS). When he 
presented at his initial evaluation at age 36 years, he had an unsteady gait, poor 
coordination, and foot dragging. He had urinary and bowel urgency with incontinence and 
sexual impotence. His symptoms were considered to be consistent with MS, and his 
differential diagnoses were spastic paraparesis and spinocerebellar degeneration. By age 49 
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years, he required a wheel chair because he could not ambulate. He developed reactive 
depression. He was treated with amitriptyline. He had excessive drowsiness and a dry 
mouth. Other problems included restless legs syndrome and obstructive sleep apnea, the 
latter treated with continuous positive airway pressure. An MRI scan of his brain when he 
was 56-years-old was unremarkable. His medical history was notable for complex partial 
seizures, glaucoma, strabismus, sensorineural hearing loss, and hyperlipidemia.
At age 60 years his mental state was normal. His speech and language were clear and 
coherent, except for mild hypophonia. There was weakness in lower extremity muscles. 
Reflexes were hyperactive in both upper and lower extremities, and he had bilateral extensor 
plantar responses. He had cerebellar ataxia on finger-to-nose testing. He was unable to 
perform heel-to-shin testing, which was possibly due to severe weakness. He had decreased 
sensation to light touch, vibration, joint position, temperature, and pinprick in his lower 
extremities. An MRI of his brain showed stable areas of T2 hyperintensity in the white 
matter of the right centrum semiovale, which was thought to be non-specific because the 
size of T2 hyperintensities had not changed in 2 years. There was no evidence of a 
widespread demyelinating process involving the periventricular white matter. The 
brainstem, cerebellum, and cervical spinal cord were unremarkable. He was diagnosed as 
having multiple system atrophy (MSA). The patient died at age 69. An autopsy limited to 
examination of the brain was performed.
METHODS
Neuropathologic methods
Macroscopic and microscopic assessments were performed at the brain bank for 
neurodegenerative disorders at the Mayo Clinic in Jacksonville, Florida. The brain bank 
operates under procedures approved by the Mayo Clinic IRB. The autopsy on this patient 
was performed after informed consent from his caregiver who had legal power-of-attorney 
for this patient. The left hemi-brain was fixed in formalin and embedded in paraffin; the 
right was frozen for research studies. The areas sampled for histology were middle frontal 
gyrus, superior temporal gyrus, inferior parietal gyrus, pre-and post-central gyri, visual 
cortex, cingulate gyrus, anterior and posterior hippocampus, amygdala, basal nucleus of 
Meynert, caudate nucleus, putamen, thalamus, midbrain, pons, medulla, cerebellum, and 
optic nerve. Paraffin-embedded 5-µm thick sections mounted on glass slides were stained 
with hematoxylin and eosin (H&E) and thioflavin S stains. Select sections were processed 
for Luxol fast blue (LFB) or periodic acid-Schiff (PAS) stain with and without diastase. 
Immunohistochemistry was performed using antibodies against α-synuclein (NACP, 1:3000 
rabbit polyclonal, Mayo Clinic antibody), TDP-43 (MC2085,13 1:2500 rabbit polyclonal, 
from Leonard Petrucelli, Mayo Clinic), CD68 (M0814, 1:1000 mouse monoclonal, DAKO), 
and neurofilament (SMI-31, 1:80000 mouse monoclonal, Covance). After immunostaining, 
the sections were briefly counterstained with hematoxylin.
Electron microscopy
Small pieces of cerebellum were fixed in 2.5% glutaraldehyde-0.1 M cacodylate buffer, 
post-fixed in 1% aqueous osmium tetroxide, stained in 2% uranyl acetate in 50% ethanol, 
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dehydrated in ethanol and propylene oxide, infiltrated and embedded in Epon 812. Thin 
sections were stained with uranyl acetate and lead citrate, and examined with a Philips 208S 
electron microscope fitted with a Gatan 831 digital camera. Images were processed with 
Adobe Photoshop CS5 software.
Genetic methods
Genomic DNA and cDNA were extracted from brain tissue using a standard protocol. The 
entire cDNA of ABCD1 was sequenced, and the consensus RefSeq accession NM_000033.3 
was used to assign all variants within the ABCD1 gene and protein. Subsequently, genomic 
DNA was sequenced to confirm the mutation found in the cDNA. (Primers are available on 
request.) For prediction of the functional consequences of the mutation in ABCD1, we used 
publically available software programs: PolyPhen-2 (http://genetics.bwh.harvard.edu/




The calculated whole brain weight was 1240 grams. Macroscopically, the cerebral 
hemisphere had a normal configuration. No obvious atrophy was evident in midbrain, pons, 
medulla, or cerebellum. On sections of the cerebellum cut in a transverse plane 
perpendicular to the long axis of the brainstem there was mild atrophy of the white matter 
and dentate nucleus (Fig. 1a). The cerebral cortex, hippocampus, basal ganglia, and 
thalamus were unremarkable. The superior cerebellar peduncle showed mild atrophy. The 
substantia nigra and locus ceruleus had decreased pigmentation.
Histologically, the cerebellar white matter had mild myelin loss with clusters of mostly 
perivascular macrophages that had granular, amphophilic-to-slightly basophilic cytoplasmic 
material (Fig. 1b–c). The material was PAS-positive and diastase-resistant (Fig. 1d), and 
cells were consistent with macrophages in that they were positive on CD68 
immunohistochemistry (Fig. 1e). The white matter lesions were more conspicuous in the 
folia than in the central white matter, but the axons were relatively preserved in the both 
regions. There was patchy Purkinje cell loss with Bergmann gliosis and scattered Purkinje 
cell axonal torpedoes, especially in the vermis. The dentate nucleus was relatively preserved, 
but the hilus had myelin loss.
The cerebral white matter had patchy and poorly circumscribed areas of myelin rarefaction 
with PAS-positive macrophages that were most frequent in the occipital lobe (Fig. 1b and f). 
Vessels in the white matter had mild arteriosclerotic medial and adventitial hyalinosis and 
mild dilation of perivascular spaces, some containing PAS-positive macrophages. In 
contrast, the neocortex was well preserved. There was no obvious neuronal loss or gliosis in 
the neocortex, hippocampus, amygdala, basal nucleus of Meynert, basal ganglia or thalamus. 
The substantia nigra had mild neuronal loss with extraneuronal neuromelanin, while other 
brainstem nuclei, including the pontine nuclei and inferior olivary nucleus, were preserved.
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The optic nerve had mild myelin rarefaction with expansion of the fibrovascular connective 
tissue septae. There were scattered clusters of PAS-positive macrophages. The optic tract 
had less obvious changes (Fig. 1g). The internal capsule, especially the posterior limb, had 
patchy myelin rarefaction and clusters of PAS-positive macrophages (Fig. 1h). The fiber 
tracts in the brainstem were also affected, especially the decussation of the superior 
cerebellar peduncle and the longitudinal fibers in the pontine base. The pyramidal tract in 
the medulla was minimally affected.
Immunohistochemistry for α-synuclein did not reveal glial cytoplasmic inclusions, which 
are the hallmark lesions of MSA. There were sparse Lewy bodies predominantly in the 
brainstem that were consistent with a coincidental age-related finding (so-called “incidental 
Lewy bodies”), since they were not associated with neuronal loss in affected nuclei. There 
was also other age-related pathology, most notably cortical amyloid plaques, with minimal 
medial temporal neurofibrillary tangles. There were no TDP-43-positive inclusions.
Electron microscopy
Electron microscopy showed that the macrophages contained membrane-bound cytoplasmic 
inclusions that had a cleft-like trilamellar membrane structure consistent with those seen in 
lipidoses (Fig. 2). Given the similarity of the macrophage inclusions to those found in X-
ALD,17, 18 we conducted genetic studies on the gene responsible for X-ALD, ABCD1.
Genetic findings
A novel ABCD1 mutation was discovered in exon 1 – p.R163G (c.487 C>G) (Fig. 3a). R163 
is a conserved residue (Fig. 3b), supporting the notion that this site is of functional 
importance and that the R-G variant is pathogenic. No other family member was available to 
show segregation of the mutation with disease phenotype, but all three prediction tools 
(PolyPhen-2, SIFT and Mutation Taster) indicated that the p.R163G mutation should be a 
damaging mutation.
DISCUSSION
We report a patient who was clinically diagnosed as having MSA in his later disease stage 
due to cerebellar and long tract signs with autonomic dysfunction. Neuropathological 
studies, especially electron microscopy, confirmed that he had cerebello-brainstem form of 
X-ALD. No blood samples were available to test for accumulation of VLCFA and given that 
the autopsy was limited to the brain, histologic studies of the adrenal were not possible. A 
diagnosis of X-ALD was never entertained during his life. He had long disease duration (35 
years) and lacked characteristic MRI findings of X-ALD (and of MSA). The major 
pathologic findings were widespread, but patchy, white matter lesions characterized by 
myelin rarefaction and perivascular clusters of PAS-positive macrophages. Electron 
microscopic analyses in the cerebellum showed trilamellar membrane structures in 
cytoplasmic inclusions typical of X-ALD. The characteristic ultrastructural findings led to 
targeted genetic studies since there was no clear family history of disease. This case 
demonstrates the continuing value of ultrastructural characterization of atypical 
neuropathological conditions.
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A review of the literature showed that most reports of cerebello-brainstem dominant form of 
X-ALD have (1) a family history of X-ALD or Addison’s disease (51.7% = 15/29, data of 5 
patients were not available), (2) adrenal insufficiency (75.0% = 24/32, data of 2 patients 
were not available), or (3) T2-weighted hyperintensities in the internal capsule, brainstem, 
and/or cerebellum (77.8% = 14/18, the data of 16 patients were not available) on MRI. The 
patient reported here did not have these characteristic features, and T2 signal abnormalities 
were interpreted as being due to microvascular pathology common in aging.
For many years, this patient carried a clinical diagnosis of and was treated for chronic 
progressive MS, but antemortem imaging studies never showed findings typical of MS. The 
pathology in our patient did not bear any resemblance to that of chronic progressive MS. In 
the later years of his 35-year disease course, his clinical diagnosis was MSA. Although he 
fulfilled criteria of probable MSA given the presence of a cerebellar syndrome, pyramidal 
symptoms and autonomic failure,19 his relatively young age of onset and long disease 
duration, as well as seizures, temporary loss of eyesight, hearing loss and sensory 
disturbance are not typical of MSA, and more compatible with X-ALD.
Based on a review of the literature of cases with adult-onset cerebello-brainstem dominant 
X-ALD (Table 1 and Fig. 4), consideration of age at onset as well as a positive family 
history may be helpful in arriving at the diagnosis. The mean age at onset of the adult-onset 
cerebello-brainstem dominant form (33 ± 11, range 20 – 71 years) is earlier than that of 
MSA (60 ± 9, range 34 – 83 years),20 although more than 10% of cases have onset after the 
age of 50 years, which is similar to MSA (Fig. 4b). Previous reports of this variant showed 
earlier ages at death (28 years, 37 years, and 46 years),9, 21, 22 and the disease duration for 
each was 6 years, 3 years, and 25 years respectively.9, 21, 22 Our patient died at an older age 
(69 years), which highlights the atypical clinical course of our patient. His other symptoms 
were common to cerebello-brainstem dominant X-ALD, including cerebellar ataxia, gait 
disturbance, speech disturbance, pyramidal signs, and autonomic failure (Fig. 4c). VLCFA 
levels were reported to be increased in 100% (30/30, data of 4 patients were not available), 
and VLCFA was the diagnostic tool used for those 30 patients. The four patients in which 
VLCFA data was not available, including our patient, (12%, 4/34) were diagnosed at 
autopsy.9, 21, 22 The antemortem clinical diagnoses of these 4 patients were 
olivopontocerebellar atrophy (OPCA),9, 21 MS or MSA [our study], or schizophrenia with 
neurological problems.22 ABCD1 mutations were identified in 8 of the 34 patients (Fig. 3c).
Our case had no hyperintensities or atrophy in the brainstem or cerebellum on MRI. In our 
review, T2-weighed hyperintensity on MRI was reported in the cerebrum in 28% (5/18, the 
data of 16 patients were not available) of cases, and it was reported in internal capsule, 
brainstem and/or cerebellum in 78% of the reported cases. Brainstem and/or cerebellar 
atrophy was found in 62% of the reported cases (20/32, the data of 2 patients were not 
available). These data seem to indicate that T2 hyperintensity (demyelination or gliosis) can 
occur before atrophy develops. These data also highlight the importance of MRI findings in 
diagnosis of this rare disorder. On the other hand, a patient has been reported with atrophy, 
but without T2 hyperintensities mimicking MSA,23 which indicates that clinicians also 
should recognize that MRI findings may not always predict disease. As some previous 
studies have reported, patients that have cerebello-brainstem dominant form have symptoms 
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that mimic MSA or OPCA,9, 21, 24–28 thus, we recommend considering X-ALD in the 
differential diagnosis of MSA, especially younger patients with atypical clinical features.
Although the mechanism of the cerebellar and brainstem dominant lesion formation is still 
unknown in these disorders, it is speculated that lipid dysfunction in myelin synthesis and 
maintenance underlies the neuropathology of MSA29 as well as X-ALD. In comparison to 
previous pathologic reports of adult-onset cerebello-brainstem dominant form of X-
ALD,9, 21, 22 the white matter lesions in our patient were mild, even in the most severely 
affected regions, namely the cerebellar white matter. There was no significant atrophy in the 
brainstem or cerebellum in our patient, while previous reports have highlighted macroscopic 
atrophy in brainstem and cerebellum. Two reported cases21, 22 had remarkable neuronal loss 
in the subcortical and brainstem nuclei, including the pontine nucleus and inferior olivary 
nucleus, similar to OPCA. In contrast, no significant neuronal loss was detected in 
subcortical or brainstem nuclei in our patient. The exception was very mild neuronal loss in 
the substantia nigra associated with incidental Lewy bodies. For reasons that are not clear, 
our patient had a relatively benign disease course that played out over several decades and 
was associated with relatively mild multifocal white matter pathology, affecting optic 
nerves, cerebral white matter, long tracts and cerebellum. The subtle perivascular lesions 
might easily have been missed and their significance attributed to age-related changes, had 
ultrastructural studies clearly indicated another possibility.
The ABCD1 mutation detected in our patient, p.R163G, has not been reported previously. It 
is located in the transmembrane domain of ATP-binding cassette transporter D1, which is 
involved in peroxisomal import of fatty acids. Other diseases causing mutations have been 
reported at the same position, including p.R163H in a symptomatic female carrier30 and 
p.R163P in two AMN patients.31, 32 These observations supports the pathogenicity of the 
mutation in our patient. Only 8 mutations have been reported to cause adult-onset cerebello-
brainstem dominant form of X-ALD (Fig. 3c).23, 28, 33–36 All of the mutations are in the 
transmembrane domain or ATP-binding cassette domain (Fig. 3c), and both domains are 
“hot spots” for mutations in ABCD1.2 The adult-onset cerebello-brainstem dominant form 
and AMN display similar features (e.g., age at onset, autonomic failure, pyramidal 
symptoms and sensory disturbance), but most cases can be distinguished by cerebellar 
dominant symptoms (Table 1 and Fig. 4b). In line with other nomenclature, we suggest that 
this disorder be named ALD-C (cerebellar variant of ALD).
This rare phenotype is observed relatively frequently in Asian countries, especially in Japan 
and South Korea (Table 1 and Fig. 4a). Previous studies estimated that the frequencies of the 
cerebello-brainstem dominant form are 1–2% globally,2 but 9% (13/145) in Japanese 
patients with X-ALD.37 Therefore, factors modulating X-ALD in Asian patients may be 
present. Intriguingly, there are some cerebellar variants in other diseases, such as the 
cerebellar variant of MSA (MSA-C)38–40 and progressive supranuclear palsy (PSP-C),41–43 
which are also more frequent in Japan than in Europe or the United States. This suggests that 
there may be environmental, epigenetic or genetic factors that may contribute to or protect 
from cerebellar predominant pathology in these disorders.
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Recently, it has been recognized that a proportion of patients with acyl-CoA oxidase 
deficiency (ACOX1; OMIM 609751) may exhibit similar clinical, radiological, and 
histopathological features to those of X-ALD, especially in the cerebello-brainstem 
form.44, 45 Inherited deficiencies of peroxisomal straight chain VLCFA β-oxidation include 
only X-ALD and straight-chain acyl-CoA oxidase deficiency. Although rare, adult-onset 
cerebello-brainstem dominant ACOX1 was reported and it should be one of differential 
diagnoses of atypical MSA as well as cerebello-brainstem dominant form of X-ALD.45
Conclusion
We described a patient who had the adult-onset sporadic cerebello-brainstem dominant form 
of X-ALD with the longest clinical course, unexpectedly mild pathological findings, and a 
new ABCD1 p.R163G substitution. We also review a total of 34 cases of adult-onset 
cerebello-brainstem dominant form of X-ALD. Currently, there is no effective treatment for 
adult-onset X-ALD, but early recognition of this rare disorder would be useful for genetic 
counselling and future therapy.46
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(a) Macroscopic finding of cerebellum. (b) LFB staining demonstrates mild myelin pallor in 
cerebellar white matter (inset shows higher magnification of area in box). (c) Perivascular 
macrophages in the cerebellar white matter have a granular amphophilic-to-slightly 
basophilic cytoplasmic material (H&E). (d) The material was PAS-positive and diastase 
resistant. (e) The cells with storage material were macrophages since they were 
immunoreactive for CD68. (f) LFB staining demonstrates myelin pallor in occipital lobe 
(inset shows higher magnification of area in box). Arrow indicates a region of myelin pallor 
in perivascular region near occipital horn of lateral ventricle. LFB staining shows patchy 
mild myelin pallor in optic tract (inset shows higher magnification of area in box) (g), and 
posterior limb of internal capsule (inset shows higher magnification of area in box) (h).
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(a) Electron micrograph of macrophages (MP) within Virchow Robin space between glia 
limitans and basal lamina (BL) of a blood vessel (V). Bar, 3 µm. (b) Higher magnification of 
MP in (a) showing cytoplasmic inclusion (arrow). * indicates the area enlarged in (c). Bar, 
0.5 µm. (c) Cleft-like tri-lamellar structures can be observed in the inclusion. Bar, 50 nm. (d) 
An inclusion is bound by membrane (outlined by arrows). Bar, 0.1 µm.
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Genetic analysis. (a) Electrochromatograph shows a novel mutation in ABCD1 gene, 
p.R163G (c.487C>G). (b) Protein sequence of R163 is highly conserved in other species. (c) 
Localization of ABCD1 mutations in cerebello-brainstem dominant form of X-ALD.
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Summary of reported cases of cerebello-brainstem dominant form of X-ALD. (a) Proportion 
of cases by ethnic group (in percent). (b) Proportion of cases by age of onset. (c) Proportion 
of cases by symptoms (in percent).
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